4D Pharma Joins The SPAC Trend To Fund Its Keytruda-Boosting Biotherapeutic

A Platform To Attract More Investors

The Leeds, UK-based company is looking to the alternative route to the US stock market to fund its live biotherapeutics platform.

Nasdaq 2021 — The company joins a trend for SPAC biotech mergers which gained momentum last year and has continued into 2021

While the US biotech sector has boomed during the pandemic, with dozens of start-ups going public via mergers with special purpose acquisition corporations (SPACs), European companies have so far largely missed out.

That is about to change, with UK-based 4D Pharma, plc due to complete a NASDAQ listing this month, by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

25 Jun 2025

• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Kymera Inks CDK2 Deal With Gilead

25 Jun 2025

• By Alaric DeArment

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

25 Jun 2025

• By Kevin Grogan

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

25 Jun 2025

• By Anju Ghangurde

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.